Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for cold tolerance in Navy personnel
NCT06011265Phase 1Completed
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Hypothermia comparing Mirabegron + Isoproterenol with Placebo + Isoproterenol (2 arms). Primary endpoints: Change in metabolic rate, Change in temperature among the top 10% of hottest pixels in the supraclavicular region and 1 more. Started Apr 2023; status: completed.
02
Drugs
mirabegron
03
Conditions
Hypothermia
Beyond the preview
Go deeper on NCT06011265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011265.